{"id":"levofloxacin-film-coated-tablet","safety":{"commonSideEffects":[{"rate":"3-9%","effect":"Nausea"},{"rate":"2-5%","effect":"Diarrhea"},{"rate":"2-4%","effect":"Headache"},{"rate":"1-3%","effect":"Insomnia"},{"rate":"<1%","effect":"Tendinitis/tendon rupture"},{"rate":"<1%","effect":"QT prolongation"},{"rate":"<1%","effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a fluoroquinolone antibiotic, levofloxacin works by binding to and inhibiting DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This leads to accumulation of DNA breaks, cell death, and bactericidal activity against a broad spectrum of aerobic gram-positive and gram-negative bacteria.","oneSentence":"Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:05.744Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections including community-acquired pneumonia"},{"name":"Acute bacterial sinusitis"},{"name":"Acute bacterial exacerbation of chronic bronchitis"},{"name":"Uncomplicated skin and skin structure infections"},{"name":"Complicated urinary tract infections"},{"name":"Acute pyelonephritis"}]},"trialDetails":[{"nctId":"NCT06216639","phase":"","title":"Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection","status":"UNKNOWN","sponsor":"National Institute of Public Health, Slovenia","startDate":"2024-02-01","conditions":"Helicobacter Pylori Infection","enrollment":2000},{"nctId":"NCT03551210","phase":"PHASE3","title":"Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2016-05-04","conditions":"Pneumonia, Bacterial","enrollment":342},{"nctId":"NCT03832465","phase":"PHASE4","title":"Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2019-06-14","conditions":"Helicobacter Pylori Infection","enrollment":20},{"nctId":"NCT02711943","phase":"","title":"Non Interventional Study of Levofloxacin in Chronic Prostatitis","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2013-07","conditions":"Chronic Prostatitis","enrollment":500},{"nctId":"NCT02352701","phase":"","title":"Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2012-12","conditions":"Helicobacter Infections","enrollment":320},{"nctId":"NCT02439632","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2014-02","conditions":"Acute Lower Urinary Tract Infection","enrollment":216},{"nctId":"NCT01761201","phase":"PHASE3","title":"\"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients\".","status":"TERMINATED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2012-01","conditions":"Latent Tuberculosis Infection, Infection in Solid Organ Transplant Recipients","enrollment":68},{"nctId":"NCT02157571","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Exacerbations of Chronic Bronchitis With Levofloxacin Hydrochloride Tablet as Active Control","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2013-06","conditions":"Acute Exacerbations of Chronic Bronchitis","enrollment":360},{"nctId":"NCT00906048","phase":"PHASE3","title":"LEVOS - Levofloxacin and Rifampicin Therapy in the Treatment of OsteoArticular Prothethic Infection","status":"TERMINATED","sponsor":"Sanofi","startDate":"2009-04","conditions":"Infection","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Leflodal film-coated tablet"],"phase":"marketed","status":"active","brandName":"Levofloxacin film-coated tablet","genericName":"Levofloxacin film-coated tablet","companyName":"Mackay Memorial Hospital","companyId":"mackay-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Bacterial infections including community-acquired pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}